Jacobson Pharma Corporation Limited (HKG:2633)
Hong Kong · Delayed Price · Currency is HKD 1.090
0.00 (0.00%)
Jul 13, 2026, 10:28 AM HKT
HKG:2633 Income Statement
Financials in millions HKD. Fiscal year is April - March.
Millions HKD. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 1,569 | 1,577 | 1,468 | 1,268 | 1,596 | |
Revenue Growth (YoY) | -0.47% | 7.43% | 15.79% | -20.55% | 10.35% |
Cost of Revenue | 891.56 | 883.96 | 847.32 | 728.68 | 975.02 |
Gross Profit | 677.9 | 692.94 | 620.48 | 538.92 | 620.52 |
Selling, General & Admin | 324.72 | 324.24 | 332.38 | 297.92 | 397.63 |
Other Operating Expenses | -34.57 | -65.74 | -23.31 | -28.27 | -25.58 |
Operating Expenses | 290.16 | 258.49 | 309.07 | 269.65 | 372.06 |
Operating Income | 387.75 | 434.45 | 311.4 | 269.27 | 248.47 |
Interest Expense | -30.71 | -41.37 | -78.71 | -61.41 | -25.69 |
Interest & Investment Income | 8.32 | 16.69 | 27.68 | 17.88 | 3.02 |
Earnings From Equity Investments | 4.68 | 0.4 | 0.17 | -1.63 | -3.77 |
Currency Exchange Gain (Loss) | 0.3 | 0.3 | -0.1 | 0.36 | 0.05 |
EBT Excluding Unusual Items | 370.34 | 410.47 | 260.44 | 224.47 | 222.08 |
Gain (Loss) on Sale of Investments | 0.24 | -2.42 | 1.62 | - | 3.3 |
Gain (Loss) on Sale of Assets | -0.18 | -4.1 | -0.05 | -3.42 | 0.25 |
Asset Writedown | -7.78 | -30.32 | -7.43 | - | 5.55 |
Other Unusual Items | - | - | - | 29.3 | 0.25 |
Pretax Income | 362.63 | 373.63 | 254.58 | 250.35 | 231.43 |
Income Tax Expense | 61.01 | 72.79 | 44.41 | 42.98 | 43.73 |
Earnings From Continuing Operations | 301.62 | 300.83 | 210.17 | 207.37 | 187.71 |
Earnings From Discontinued Operations | - | - | 80.61 | 75.84 | - |
Net Income to Company | 301.62 | 300.83 | 290.78 | 283.21 | 187.71 |
Minority Interest in Earnings | - | - | -23.81 | -32.17 | -10.04 |
Net Income | 301.62 | 300.83 | 266.97 | 251.04 | 177.67 |
Net Income to Common | 301.62 | 300.83 | 266.97 | 251.04 | 177.67 |
Net Income Growth | 0.26% | 12.68% | 6.34% | 41.30% | 2.28% |
Shares Outstanding (Basic) | 1,998 | 1,986 | 1,920 | 1,911 | 1,916 |
Shares Outstanding (Diluted) | 1,998 | 1,986 | 1,920 | 1,912 | 1,916 |
Shares Change (YoY) | 0.59% | 3.42% | 0.45% | -0.21% | -0.03% |
EPS (Basic) | 0.15 | 0.15 | 0.14 | 0.13 | 0.09 |
EPS (Diluted) | 0.15 | 0.15 | 0.14 | 0.13 | 0.09 |
EPS Growth | -0.33% | 8.96% | 5.89% | 41.57% | 2.30% |
Free Cash Flow | - | 278.39 | 354.85 | 567.09 | 343.08 |
Free Cash Flow Per Share | - | 0.14 | 0.18 | 0.30 | 0.18 |
Dividend Per Share | 0.090 | 0.090 | 0.055 | 0.052 | 0.039 |
Dividend Growth | - | 63.64% | 6.18% | 33.51% | 68.70% |
Gross Margin | 43.19% | 43.94% | 42.27% | 42.52% | 38.89% |
Operating Margin | 24.71% | 27.55% | 21.22% | 21.24% | 15.57% |
Profit Margin | 19.22% | 19.08% | 18.19% | 19.80% | 11.13% |
Free Cash Flow Margin | - | 17.66% | 24.18% | 44.74% | 21.50% |
EBITDA | 496.74 | 543.44 | 415.94 | 380.38 | 391.76 |
EBITDA Margin | 31.65% | 34.46% | 28.34% | 30.01% | 24.55% |
D&A For EBITDA | 108.99 | 108.99 | 104.53 | 111.12 | 143.29 |
EBIT | 387.75 | 434.45 | 311.4 | 269.27 | 248.47 |
EBIT Margin | 24.71% | 27.55% | 21.22% | 21.24% | 15.57% |
Effective Tax Rate | 16.83% | 19.48% | 17.45% | 17.17% | 18.89% |